Adjuvant Pembrolizumab (NSCLC), Elacestrant, & Pirtobrutinib
OncoPharm
00:00
Keynote-091 Disease-Free Survival Results
John outlines Keynote-091 design and reports disease-free survival benefit (HR 0.73) and median DFS with pembrolizumab versus placebo.
Play episode from 02:33
Transcript
